Labcorp Holdings Inc. LH

What this company does

Labcorp Holdings Inc. provides its services to a broad range of customers across two business segments. During 2025, the Company's nearly 71,000 employees served clients in approximately 100 countries and performed more than 750 million tests for patients around the world. The Company is organized under two segments: Dx, which includes routine testing and specialty/esoteric testing, and BLS, consisting of Central Laboratory and ED businesses. During 2025, the Dx segment generated $10,876.5 million in revenues, offering a comprehensive menu of core and specialty testing through an integrated network of primary and specialty laboratories across the U.S. and Canada, with more than 2,200 patient service centers and more than 7,000 in-office phlebotomists. BLS serves pharmaceutical, biotechnology and diagnostic companies worldwide, operating a global network with expertise across early development and clinical trial execution in multiple therapeutic areas, and generated $3,098.2 million in revenues during 2025. During 2025, the Company invested $582.0 million in strategic business acquisitions.

Written from the business description in LABCORP HOLDINGS INC.'s annual report to the U.S. Securities and Exchange Commission, filed 24 February 2026. Every sentence was checked against that document before publication.